Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02345889 · ClinicalTrials.gov registry record · NA
A 4-arm Clinical Trial of Fuse®, EndoCuff™, EndoRings™ and Standard Colonoscopy
A NA study, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 1,262
- Enrollment target
NCT02345889: Completed NA study, sponsored by Indiana University.
NCT02345889 is a NA study that has completed, run by Indiana University. The registered enrollment target is 1,262 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02345889, a NA study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,262 participants
- Enrollment target
Study Summary
Adenoma detection rate (ADR) is a validated marker for reducing the risk of interval colorectal cancer after a screening colonoscopy. Recent studies suggest that novel devices attached to the colonoscope tip may improve the ADR of doctors performing a screening procedure
Interventions
- DEVICE Standard Colonoscopy
- DEVICE Colonoscopy with EndoCuff™
- DEVICE FUSE® Colonoscopy
- DEVICE Colonoscopy with EndoRings™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,262 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-12 |
| Phase | NA |
What the finished NCT02345889 record still lists
NCT02345889 is an interventional study that assigns participants to a tested intervention. Its 1,262 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (10% lower).
The record links to 0 conditions, and to 4 interventions - of which Standard Colonoscopy is the first listed.
NCT02345889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02345889 about?
NCT02345889 is a clinical study titled "A 4-arm Clinical Trial of Fuse®, EndoCuff™, EndoRings™ and Standard Colonoscopy". Adenoma detection rate (ADR) is a validated marker for reducing the risk of interval colorectal cancer after a screening colonoscopy. Recent studies suggest that novel devices attached to the colonoscope tip may improve the ADR of doctors performing a screening procedure
What is the current status of trial NCT02345889?
This trial is currently completed. It is a NA study. The enrollment target is 1,262 participants. The study started on 2015-02. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02345889?
The interventions under investigation include: Standard Colonoscopy (DEVICE), Colonoscopy with EndoCuff™ (DEVICE), FUSE® Colonoscopy (DEVICE), Colonoscopy with EndoRings™ (DEVICE).
Who is sponsoring clinical trial NCT02345889?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02345889's enrollment target sits among peer trials
1,262 79th of 2000 higher than 1,922 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- NCT06712316 · 1,260 participants · Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- NCT06812273 · 1,260 participants · NA
Mediators and Moderators of Auditory Training
- NCT06931340 · 1,260 participants · Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia